Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | CuttingEdgeInfo Reports | Designing Patient Communications Programs (PH131) Education, Adherence, and Disease Management

Designing Patient Communications Programs (PH131) Education, Adherence, and Disease Management

Improve Patient Communication and Generate Sales

What does an effective patient communications program look like? In today's information-hungry environment, it takes more than a company website to motivate patients. Although developing a superior program involves vetting a dizzying number of options, if your brand succeeds, the benefits are palpable: earn customers' trust, win higher brand awareness and loyalty, improve patient adherence, and generate sales.

Improve your campaigns to make them resonate with patients. The study's findings and expert advice address pharmaceutical executives' most pressing questions. Some of these questions include:

What measureable patient education goals should I have in place?

Patient communications is increasingly being tied to global brand strategy. Examine our extensive patient communication brand profiles, including performance metrics specific to therapeutic areas, responsibilities for certain activities, which tools brand teams use, the level of staffing required and length of development. The study also includes rankings of various tools that provide insight into their effectiveness.

Do I have the resources to achieve these goals?

Our data benchmarks reveal real-company budgets and staffing for more than 30 brands, evaluating the efficiency of up to 19 different tools. The study's data analysis and recommendations allow executives to efficiently allocate resources to meet their needs.

Is my patient education collateral objective and accessible?

Sophisticated tools are not useful if the content is difficult to understand or doctors consider it biased or too branded. The report's actionable strategies for improving your messages are easy to implement and aim to satisfy the key players.

What impact will social media have?

With new media seemingly permeating all parts of drug companies' marketing and sales efforts, it can be difficult to understand which are the most useful and effective. Find trend analysis and commentary from top executives who weigh in on the latest media trends and their contributions to patient education. The study also includes recommendations to overcome regulatory obstacles.

Companies Included in Report

In all, 33 companies contributed to this report, including pharma companies of all sizes as well as consultants specializing in accessibility and distribution of patient communication materials. Brands profiled for this report are owned and managed by the following companies:

* Allergan

* AstraZeneca

* Boehringer-Ingelheim

* Eli Lilly

* EUSA Pharma

* Genzyme

* Grupo Farma

* OxThera

* Pfizer

* Sanofi-Aventis

* Schering-Plough

* Teva

* UCB

* Upsher-Smith

Published 2009

293 Pages

600+ Metrics

190+ Charts and Diagrams

Table of Contents
Price: $7,685.00 / €5,136.65

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions